The National Marrow Donor Program® (NMDP) is committed to research aimed at increasing opportunities for and improving outcomes of bone marrow and cord blood transplants (also called BMT). The NMDP operates Be The Match® and is also involved in several transplant-related clinical trials. It is involved in many of these trials as part of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).
The NMDP and its research arm, the Center for International Blood and Marrow Transplant Research® (CIBMTR), collect and study data to learn how to improve patient outcomes. We design, conduct and support clinical studies that involve large numbers of patients from multiple transplant centers — the types of studies that are needed to answer critical questions in the field of blood and marrow transplantation.
If you are a patient considering a blood or marrow transplant, you may have the option to be part of a clinical trial for one or more parts of your treatment. Your doctor may tell you about a trial, or you may be looking for more treatment options. This page lists current and upcoming transplant-related clinical trials conducted by the NMDP through its partnership in the CIBMTR and/or BMT CTN.
BMT CTN Clinical Trials
The SCURT Study (BMT CTN 0601): Unrelated donor transplantation for Children with Severe Sickle Cell Disease (SCD) — A Phase II multicenter study for children with severe SCD age 3-16. Eligible children must have at least one of these symptoms:
- Stroke or other SCD brain complication
- Severe chest pain more than once
- Severe pain problems more than twice
You can talk with a patient services coordinator at Be The Match about the study or view a list of participating sites (PDF) participating in the study.
- Fludarabine-based Conditioning for Allogeneic Marrow Transplantation from HLA-compatible Unrelated Donors in Severe Aplastic Anemia — A Phase I/II multi-center study for allogeneic marrow transplantation from matched unrelated donors in patients 65 years of age or younger with severe aplastic anemia (SAA). Enrollment beginning summer of 2005.
- T cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients with AML in First or Second Morphologic Complete Remission — A Phase II multi-center trial for patients 18 to 60 years of age with AML in First or Second remission with an HLA-identical sibling donor assess the efficacy of HLA-identical sibling transplantation using PBSC grafts processed by the CliniMACS system and employing an intensive pre-transplant cytoreductive regimen. Enrollment beginning spring of 2005.
- Rituxan/BEAM vs. Bexxar/BEAM for persistent or relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin's Lymphoma — A Phase III, multi-center trial, comparing progression-free survival (PFS) after autologous hematopoietic stem cell transplantation using a standard Rituxan plus BEAM transplant regimen versus a regimen adding Bexxar to BEAM in patients 18-80 years of age that have persistent or recurrent diffuse large B-cell lymphoma. Enrollment beginning summer of 2005.
To find information about other transplant-related trials, see Finding a Clinical Trial.
We also develop and support many retrospective research studies (studies that examine data from previous transplants). By looking at the data in new ways, researchers can gain knowledge to guide future transplant choices and treatment strategies. To find out more about these research studies, see:
http://www.nmdpresearch.org.